SCHEMBL6432352

SCHEMBL6432352

CS(=O)(=O)Nc1ccc(Cl)cc1NC(=O)Nc1cccc(C(F)(F)F)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NTRK1 P04629 1/20 0.68
▸ CDK19 Q9BWU1 1/20 0.68
▸ MEN1 O00255 4/20 0.65
▸ KMT2A Q03164 4/20 0.65
▸ GRIK1 P39086 3/20 0.65
▸ KDR P35968 1/20 0.59
▸ IDH1 O75874 5/20 0.59
▸ PTGES O14684 1/20 0.58
▸ ALOX5 P09917 1/20 0.58
▸ IDH2 P48735 2/20 0.56
▸ MAPT P10636 3/20 0.54
▸ HTT P42858 2/20 0.54
▸ RAB9A P51151 1/20 0.54
▸ TRPV1 Q8NER1 1/20 0.53
▸ CA12 O43570 1/20 0.53
▸ CA1 P00915 1/20 0.53
▸ CA2 P00918 1/20 0.53
▸ CA9 Q16790 1/20 0.53
▸ CNR2 P34972 1/20 0.53
▸ POLB P06746 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14113154 0.84 P2RX1 (0.66) NTRK1CDK19MEN1KMT2AGRIK1
SCHEMBL14459439 0.82 KDR (0.76) NTRK1CDK19MEN1KMT2AGRIK1
SCHEMBL5597796 0.82 NTRK1 (0.79) NTRK1CDK19MEN1KMT2AGRIK1
SCHEMBL3966450 0.82 NTRK1 (0.71) NTRK1CDK19MEN1KMT2AGRIK1
SCHEMBL1463419 0.81 NTRK1 (0.81) NTRK1CDK19MEN1KMT2AGRIK1
SCHEMBL1463468 0.81 NTRK1 (1.00) NTRK1CDK19MEN1KMT2AGRIK1
SCHEMBL29763181 0.81 NTRK1 (1.00) NTRK1CDK19MEN1KMT2AGRIK1
SCHEMBL1462338 0.81 NTRK1 (0.73) NTRK1CDK19MEN1KMT2AGRIK1
SCHEMBL1463283 0.80 NTRK1 (0.76) NTRK1CDK19MEN1KMT2AGRIK1
SCHEMBL8372525 0.80 NTRK1 (0.71) NTRK1CDK19MEN1KMT2AGRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050080112-A1 Compounds for use in disorders associated with mast cell or basophil acitvity POSEIDON PHARMACEUTICALS A/S (DK) 2005-04-14 — — US claimed
US-20050080112-A1 Compounds for use in disorders associated with mast cell or basophil acitvity POSEIDON PHARMACEUTICALS A/S (DK) 2005-04-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080112-A1 Compounds for use in disorders associated with mast cell or basophil acitvity CPA3, HNMT, CMA1 NTRK1 2665/4885CDK19 3829/4885MEN1 903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback